Clinical trial
Study of an Extended-Release, Crystalline Formulation of Recombinant Human…
NCT00297713 · Altus Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00297713 |
|---|---|
| Title | Study of an Extended-Release, Crystalline Formulation of Recombinant Human Growth Hormone (ALTU-238) in Growth Hormone Deficient Adults to Determine Pharmacokinetics, Pharmacodynamics, and Drug Safety |
| Official title | A Phase II, Multi-Center, Multi-Dose, Randomized, Open-Label, Parallel Group Study of an Extended-Release, Crystalline Formulation of Recombinant Human Growth Hormone (ALTU-238) in Growth Hormone Deficient Adults to Determine Pharmacokinetics, Pharmacodynamics, and Drug Safety |
| Lead sponsor | Altus Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Adult Growth Hormone Deficiency |
| Intervention type | Drug |
| Interventions | ALTU-238 |
| Enrollment | 12 |
| Start date | Jul 1, 2005 |
| Completion | Jun 1, 2006 |
| First posted | Mar 1, 2006 |
| Last update posted | Dec 13, 2006 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: